Take a peek here-- This stk has been as high as $10. Nuclear fuel stks are getting a big allotment in the budget. Not exactly what these guys do but they have an update coming March 14.
.
NuScale Power Corporation (SMR)-
NYSE - Nasdaq Real Time Price. Currency in USD
3.8400+0.3900(+11.30%)
As of 10:46AM EST.
Lizard God is back!Made $.60 on STI $3.60, thanks Stoney!
Used it a half dozen times. Not sure how they make money though. I guess title companies pay. And banks. Somebody must.DocuSign 'creeps higher on the activist watchlist,' says Dealreporter » 10:14 DOCU
I would watch this. Stk sold off but it's a good name. We have to get past this COVID comparisons or whatever when nobody would sign anything in person but without that-- signing for anything in person is a huge pain in the ass and this is good idea.
I always wondered why this co didn't broaden their offerings to more tech protect areas.. you know you buy something very high value like a car and then prove it's you.
I just had to use Docusign in a very high tension moment up in Ct with my accountant. And it worked.
Made $.60 on STI $3.60, thanks Stoney!
Used it a half dozen times. Not sure how they make money though. I guess title companies pay. And banks. Somebody must.
LifeMD sees FY24 revenue at least $200M , consensus $191.52M » 16:19 LFMD
LifeMD reports Q4 EPS 15c, consensus (14c) » 16:16 LFMD
TOMORROW'S GUMMY TODAY-!
LFMD LifeMD, Inc.
$7.95-0.05(-0.62%)4:00 PM 03/11/24
NASDAQ |$USD |Post-Market:$8.31+0.36(+4.53%)<----------5:52 PM
- Beneficial owner of Perspective Therapeutics(CATX)Lantheus purchased 60,431,039 shares of company stock at 95c per share for a total transaction amount of $57,409,487
- Company Profile
![]()
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
*** THAT $15 IS $2 ABOVE THE CURRENT PRICE*********
- Beneficial Owner of 89Bio(ETNB)RA Capital purchased 1,350,000 shares of company stock at $15.35 per share for a total transaction amount of $20,722,500
- Company Profile
![]()
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
- Director of Keurig Dr Pepper(KDP)Peter Harf purchased 171,821 shares of company stock at $29.10 per share for a total transaction amount of $4,999,991
- Director of EchoStar(SATS)James DeFranco purchased 90,000 shares of company stock at $13.21 per share for a total transaction amount of $1,188,603